The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

Regulators approved higher deductible limits for health plans in 2026, but stressed reforms are needed to tackle affordability concerns and ensure Bay Staters don't end up "self-rationing" care.